Natera, Inc. (NASDAQ: NTRA) co-founder Sheena Jonathan sold a total of 3,664 shares of the company's common stock during January 20 and 21, 2026, accruing roughly $1.44 million from the transactions. The share prices during these sales fluctuated between $234.1157 and $235.8183 per share.
On January 20, Jonathan sold 2,981 shares at an average price of $234.7384. The following day, she distributed multiple sales: 93 shares at $235 each, 2,470 shares at a weighted mean price of $234.1157 (with individual prices ranging from $234.04 to $234.87), and 600 shares at an average price of $235.8183 (price range of $235.5650 to $236.1850). Additionally, on January 20, she exercised 191 Restricted Stock Units (RSUs), each convertible into one share of Natera common stock.
Post these trades, Jonathan's direct holdings in Natera stood at 264,078 shares. She also retains indirect ownership of 22,532 shares through each of two separate trusts: Caraluna 1 Trust and Caraluna 2 Trust.
Concurrently, Natera announced impressive preliminary fourth-quarter 2025 performance figures, forecasting a revenue surge near 40% compared to the previous year, exceeding analyst predictions. This revenue growth was supported by a 17% increase in test volume, reflecting heightened demand for the company's diagnostic offerings.
Financial analysts at Canaccord Genuity affirmed their Buy rating on Natera, setting a price target of $285.00, citing strong preliminary financial data. Meanwhile, the company disclosed a collaborative effort with biopharmaceutical firm Exelixis on a pivotal phase 3 clinical trial targeted at colorectal cancer patients. This study leverages Natera’s Signatera test technology to detect molecular residual disease—indicating minimal residual cancer presence post-treatment.
Furthering innovation, Natera introduced a novel artificial intelligence (AI) model to augment molecular residual disease assessment in cancer patients. This model synthesizes multiple data modalities to enhance the accuracy and robustness of the Signatera MRD test.
Highlighting its academic impact, the Signatera test was employed in a clinical study published in JAMA Oncology. The research demonstrated survival improvements among colorectal cancer patients treated with the drug celecoxib, further underscoring the clinical utility of Natera's technologies.
Looking ahead, Natera plans to present findings from its EXPAND clinical trial related to fetal genetic screening at the upcoming 2026 Society for Maternal-Fetal Medicine meeting, signaling ongoing progress in prenatal diagnostics.